Moderna Pushes mRNA Into In Vivo CAR-T, Targeting a New Bet in Autoimmune Disease

CAR-T has usually meant removing a patient’s immune cells, modifying them, expanding them, and then infusing them back into the body. That process is expensive, slow, and difficult to scale broadly. Moderna is now turning its attention to another path: making the body itself a factory for cell engineering, generating CAR-T cells directly in vivo that can attack diseased cells.

According to Fierce Biotech, Moderna disclosed its first in vivo CAR-T candidate, mRNA-6007, at an investor event. Its initial focus is B cell-mediated autoimmune diseases, including systemic lupus erythematosus. The company plans to begin clinical development in 2027, which also means its mRNA and lipid nanoparticle technologies are extending from vaccines and protein-replacement thinking into immune-cell reprogramming.

The central idea behind this type of therapy is to deliver mRNA encoding a CAR into specific T cells in the body, causing them to temporarily express a receptor capable of recognizing target cells and thereby clearing disease-related B cells. If it works, it could avoid the waiting time and personalized manufacturing bottlenecks of traditional ex vivo CAR-T production, and could also bring treatment for severe autoimmune disease closer to a repeatable, adjustable drug model.

But the publicly available information remains quite limited. mRNA-6007 has not yet entered human trials, and what outsiders can assess is mainly the technical approach and development timeline, rather than evidence of efficacy. The real questions will be whether delivery is precise enough, whether the duration of CAR expression can be controlled, whether B cell clearance brings infection risks, and whether patients whose immune systems are already dysregulated can tolerate this kind of intervention.

Background Context

In vivo CAR-T has regained momentum in recent years not only because of manufacturing efficiency, but also because the range of diseases is being reimagined. Early studies have already produced signals of deep responses in some patients with blood cancers. In autoimmune disease, researchers hope to achieve longer remissions in refractory diseases by resetting or deeply weakening pathogenic B cells. Moderna’s entry adds a platform player skilled in mRNA delivery and rapid design to the competition.

For Moderna, mRNA-6007 also carries strategic significance. After the vaccine peak receded, the market has continued to ask whether its platform can support more high-value therapies. In vivo CAR-T offers an answer that is both large enough and difficult enough: if successful, it would not merely add a product, but prove that mRNA can be used to write immune-cell functions in real time inside the human body; if it fails, the problem will also fall very clearly on delivery, duration, and the boundaries of safety.